Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/1984
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBUYSE, Marc-
dc.contributor.authorQuinaux, E-
dc.contributor.authorCORTINAS ABRAHANTES, Jose-
dc.contributor.authorTournigand, C-
dc.contributor.authorCervantes, A-
dc.contributor.authorFiger, A-
dc.contributor.authorAndré, Thierry-
dc.contributor.authorTabah-Fisch, I-
dc.contributor.authorDe Gramont, A-
dc.date.accessioned2007-11-09T15:23:36Z-
dc.date.available2007-11-09T15:23:36Z-
dc.date.issued2006-
dc.identifier.citationANNALS OF ONCOLOGY, 17. p. 115-115-
dc.identifier.issn0923-7534-
dc.identifier.urihttp://hdl.handle.net/1942/1984-
dc.description.abstractBackground: In the OPTIMOX1 study, previously untreated patients, (pts) with advanced CRC were randomized to either FOLFOX4 every 2 wks until progressio (arm A), or FOLFOX7 (arm B). There was no difference between arms in response rate, progression-free survival, and overall survival (OS)[Tournigand, JCO 2006;24:394]. The effect of oxaliplatin reintroduction on survival was inconclusive as a significant number of pts received oxaliplatin in both arms after being taken off the study. This retrospective analysis evaluated the effect of oxaliplatin reintroduction on OS. Methods: The % of pts with oxaliplatin reintroducion was calculated in each center regardless of treatment arm, number of pts, or whether reintroduction was per protocol. A Cox model was used to analyze impact of oxaliplatin reintroduction on survival, after adjustment for all baseline covariates, and using random effects to account for the fact that % pts with oxilaplatin reintroduction was estimated in each center. Centers were grouped into 4 reintroduction classes according to o% pts with oxaliplatin reintroduction (0, 1–20, 21–40, and >40). The hazard ratio (HR; adjusted for all baseline covariates) was calculated for each reintroduction class. Results: After adjustment for all other factors,% pts with oxaliplatin reintroduction had a highly significant impact on survival (p<0.001). Reintroduction class also had a significant impact on survival, after adjustment for all other factors (p=0.02; Table below). Median survival increased from 15 months in the 0% to 23 months in the >40% reintroduction class.-
dc.languageEnglish-
dc.language.isoen-
dc.publisherOXFORD UNIV PRESS-
dc.titleAnalysis of oxaliplatin reintroduction in patients with advanced colorectal cancer (CRC) treated with FOLFOX4 or FOLFOX7 in the optimox study-
dc.typeJournal Contribution-
dc.identifier.epage115-
dc.identifier.spage115-
dc.identifier.volume17-
local.format.pages1-
local.bibliographicCitation.jcatM-
dc.description.notesInt Inst Drug Dev, Brussels, Belgium. Hasselt Univ, Ctr Stat, Hasselt, Belgium. Hop St Antoine, Med Oncol Serv, F-75571 Paris, France. Univ Hosp Valencia, Valencia, Spain. Elias Sourasky Med Ctr, Inst Oncol, Tel Aviv, Israel. Hop Tenon, Med Oncol Serv, F-75970 Paris, France. Sanofi Aventis, Paris, France.-
local.type.refereedRefereed-
local.type.specifiedMeeting Abstract-
dc.bibliographicCitation.oldjcatA5-
dc.identifier.isi000248078900340-
item.fulltextNo Fulltext-
item.accessRightsClosed Access-
item.fullcitationBUYSE, Marc; Quinaux, E; CORTINAS ABRAHANTES, Jose; Tournigand, C; Cervantes, A; Figer, A; André, Thierry; Tabah-Fisch, I & De Gramont, A (2006) Analysis of oxaliplatin reintroduction in patients with advanced colorectal cancer (CRC) treated with FOLFOX4 or FOLFOX7 in the optimox study. In: ANNALS OF ONCOLOGY, 17. p. 115-115.-
item.contributorFiger, A-
item.contributorTournigand, C-
item.contributorDe Gramont, A-
item.contributorCORTINAS ABRAHANTES, Jose-
item.contributorBUYSE, Marc-
item.contributorAndré, Thierry-
item.contributorCervantes, A-
item.contributorQuinaux, E-
item.contributorTabah-Fisch, I-
crisitem.journal.issn0923-7534-
crisitem.journal.eissn1569-8041-
Appears in Collections:Research publications
Show simple item record

Page view(s)

12
checked on Jul 2, 2022

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.